Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

THEMIS MEDICARE LTD. - 530199 - Board to consider Dividend

 Themis Medicare Ltd has informed BSE that a meeting of the Board of Directors ot the Company is scheduled to be held on May 21, 2022, inter alia, to transact the tollowing business :1. To consider the Audited Financial Results for the Quarter/Year ended on March 31, 2022,2. To consider recommending Dividend if any on the equity shares of the Company for the financial year 2021-22.Further in continuation of thd Company''s letter dated March 25, 2022, the Trading Window in respect of dealing in the Company''s Securities was closed for all Directors/Designated Employees from the opening of the trading hours on ApriI 01, 2022, which shall remain closed till the closure of trading hours on May 23, 2022 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ("the Code') adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time.
12-05-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Board Meeting Intimation for Intimation Of Date Of Board Meeting & Closure Of Trading Window.

 THEMIS MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/05/2022 ,inter alia, to consider and approve Please be informed that a meeting of the Board of Directors of Themis Medicare Limited is scheduled to be held on Saturday, 21.05.2022 inter alia, to transact the following business: 1. To consider the Audited Financial Results for the Quarter/Year ended on 31.03.2022, 2. To consider recommending Dividend if any on the equity shares of the Company for the financial year 2021-22. Further, in continuation of our Letter dated 29.03.2022, the Trading Window in respect of dealing in the Company's Securities was closed for all Directors/Designated Employees from the opening of the trading hours on Friday, 01.04.2022, which shall remain closed till the closure of trading hours on 23.05.2022 (both days inclusive) i.e. till the completion of 48 hours after the declaration of financial results as per the policy for prohibition of Insider Trading ("the Code") adopted by the Company pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time.
12-05-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Outcome Of Circular Resolution Passed By Board Of Directors Of The Company On May 10, 2022.

 With reference to the above, we would like to inform you that Board of Directors of the Company has approved and passed following resolutions by circulation on dated May 10, 2022. 1. Approved Notice of the Postal Ballot for re-appointment of Dr. Dinesh S. Patel as the Whole Time Director and Dr. Sachin D. Patel as the Managing Director and Chief Executive Officer for further period of five years. 2. Appointed CS Shirish Shetye (FCS 1926), or failing him, CS Aparna P. Joshi (FCS 7172) or failing her, CS Vaibhav S. Velankar (FCS 11448), Designated Partners of M/s. SAV & Associates LLP, Practicing Company Secretaries, Mumbai. 3. Appointment of Central Depository Services (India) Ltd. ("CDSL") to provide the service of E-Voting Facility for Postal Ballot. You are requested to take the same on your record.
10-05-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2

 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company THEMIS MEDICARE LTD. 2 CIN NO. L24110GJ1969PLC001590 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* 2021-22, 2022-23 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)2021-21, 2021-22 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-SANGAMESHWAR IYERDesignation :-COMPANY SECRETARY AND COMPLIANCE OFFICER Name of the Chief Financial Officer :- TUSHAR DALAL Designation : -CHIEF FINANCIAL OFFICER Date: 10/05/2022
10-05-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayTHEMIS MEDICARE LTD. 2CINL24110GJ1969PLC001590 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 13.61 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: SANGAMESHWAR IYER Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: sangameshwar.iyer@themismedicare.com Name of the Chief Financial Officer: TUSHAR DALAL Designation: CHIEF FINANCIAL OFFICER EmailId: tushar.dalal@themismedicare.com Date: 29/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
29-04-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Compliance -40(9)

 Enclosed herewith please find Compliance Certificate issued by M/s. V. Laxman & Co Practicing Company Secretaries for the year ended 31st March, 2022 in terms of Regulation 40(9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. This may be taken as compliance under Regulation 40(9) of the Listing Regulations.
25-04-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Compliance Certificate For The Period March 31, 2022.

 As per the requirement of Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2018, we hereby confirm that activities in relation to share transfer facility are maintained during the period April 01, 2021 to March 31, 2022 (both days inclusive) by the Company''s Registrar and Share Transfer Agent, viz., Link lntime India Private Limited, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number : INR000004058.
18-04-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 We are enclosing herewith a Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2022 received from Link lntime India Pvt. Ltd., Registrar and Share Transfer Agent of our Company.
14-04-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Closure of Trading Window

 We would like to inform you that as per the Company''s minimum Standards Code of Conduct to regulate, monitor and report trading by its Employees and other Connected Persons under SEBI (Prohibition of Insider Trading) Regulations, 2015 (as amended) (PIT Regulations) and pursuant to BSE Circular Ref No: LIST/COMP /01/2019-20 dated 2nd April, 2019 and NSE Circular Ref No. NSE/CML/2019/11 on the provisions of Clause 4 of the Schedule B of the PIT regulations, the Trading Window for dealing in the Securities of the Company shall remain closed on and from Friday 1st April, 2022 and will re-open after completion of 48 hours from the declaration of financial results for the quarter and year ended 31st March, 2022 by the Board of Directors of the Company. The same has been intimated to all the directors, officers and designated employees of the Company.
29-03-2022
Bigul

THEMIS MEDICARE LTD. - 530199 - Announcement under Regulation 30 (LODR)-Change in Directorate

 With reference to letter dated 11.02.2022 and Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A of Part A of Schedule III to the said Regulations, we wish to inform that the present tenure of Mrs. Jayshree Dinesh Patel, Whole Time Director ends on 27th March, 2022 and stepped down from the office of Directors w.e.f. closure of business hours on 27th March, 2022. We have annexed herewith the disclosures pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 read with SEBI circular no CIR/CFD/CMD/4/2015 dated 09th September, 2015 relating to resignation appointment Annexure I. This may be taken as compliance under the Listing Regulations. Kindly take the same on record and acknowledge receipt.
28-03-2022
Next Page
Close

Let's Open Free Demat Account